NEW YORK, May 15 - Tranzyme and Quark Biotech have inked a multi-year research and licensing collaboration, Tranzyme said today.
Privately held Tranzyme will give Quark non-exclusive worldwide rights to its gene-expression and drug-discovery technologies TranzVector and TranzAssay in exchange for undisclosed annual research funding and milestone payments, the firms said.
In addition, Tranzyme, whose technology focuses on neurosensory diseases, will receive an equity investment from Quark and pocket undisclosed royalties from any products that happen to be developed.
Click here for more information.